Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Jun 11, 2014
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Clinical or Histological diagnosis of germ cell tumors
- • Metastatic disease
- • Poor prognostic category according to the International Germ Cell Collaborative Group (IGCCCG) classification
- • No prior chemotherapy for metastatic disease
- Exclusion Criteria:
- • Unwillingness to accomplish the study procedures
- • Any existing co-morbidity that could limit the administration of high dose chemotherapy
- • Any psychiatric disorder that could impact on the study compliance
About Fondazione Irccs Istituto Nazionale Dei Tumori, Milano
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano is a leading cancer research and treatment institution in Italy, dedicated to advancing the understanding and management of oncological diseases. As a prominent clinical trial sponsor, the foundation focuses on innovative research aimed at developing new therapeutic strategies and improving patient outcomes. With a commitment to translational medicine, it collaborates with a network of national and international partners to facilitate cutting-edge clinical trials, enhance cancer care, and contribute to the global body of oncological knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, , Italy
Patients applied
Trial Officials
Andrea Necchi, MD
Principal Investigator
Istituto Nazionale dei Tumori, Milano Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials